One of the first radiopharmaceuticals for this purpose was [68Ga]Ga-PSMA-11, which has been included in national and european prostate cancer guidelines [3] based on the diagnostic superiority of [68Ga]Ga-PSMA-11 compared to [11C]C-choline and [18F]F-choline already reported in the scientific literature [4]. The gene discussed is FOLH1; the disease is prostate carcinoma.